OAK, a phase III advanced nonesmall-cell lung cancer (NSCLC) trial, compared the investigational drug atezolizumab with the standard chemotherapy agent docetaxel. The patient-reported outcomes data revealed that atezolizumab prolonged the time to the worsening of disease-related symptoms, such as chest pain, and maintained patients' health-related quality of life. These data further support the use of atezolizumab in the treatment of advanced NSCLC. Background: The randomized phase III OAK (a study of atezolizumab compared with docetaxel in participants with locally advanced or metastatic nonesmall-cell lung cancer [NSCLC] who have failed platinum-containing therapy) trial investigated the antieprogrammed cell death ligand 1 (PD-L1) antibody atezolizumab for advanced or metastatic, previously treated, NSCLC. Atezolizumab significantly improved overall survival (OS) compared with docetaxel (hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.62-0.87; P ¼ .0003; median OS, 13.8 vs. 9.6 months, respectively). Patient-reported outcomes (PROs) were collected to evaluate disease-related symptoms and health-related quality of life (HRQoL) to support the finding of a survival benefit. Patients and Methods: The first 850 patients were randomized to receive atezolizumab (1200 mg every 3 weeks) or docetaxel (75 mg/m 2 every 3 weeks). PROs were collected on day 1 of cycle 1, day 1 of every subsequent cycle, and at the end-of-treatment visit for patients who completed ! 1 baseline and 1 postbaseline PRO assessment. The European Organisation for the Research and Treatment of Cancer QoL questionnaire and lung cancer module were used to assess PROs. Results: Atezolizumab delayed the time to deterioration (TTD) in physical function (HR, 0.75; 95% CI, 0.58-0.98) and role function (HR, 0.79; 95% CI, 0.62-1.00) and numerically improved patients' HRQoL from baseline compared with docetaxel. Atezolizumab also prolonged the TTD in chest pain (HR, 0.71; 95% CI, 0.49-1.05; P ¼ .0823), although both arms showed an objective reduction relative to baseline. Overall, the patients had no clinically significant worsening in treatment-related symptoms, although the scores favored atezolizumab. Conclusion: These PRO data support the clinical benefit of atezolizumab in patients with previously treated advanced or metastatic NSCLC. Atezolizumab prolonged the TTD of patients' limitations in role and physical functions compared with docetaxel.
Introduction
Atezolizumab is a humanized, engineered IgG1 monoclonal antibody that selectively targets human programmed cell death ligand 1 (PD-L1), blocking its interactions with the receptors programmed cell death 1 and B7.1. This reverses tumor immunotolerance by evasion of effective immunosurveillance and reestablishes adaptive immune responses against cancer. [1] [2] [3] Atezolizumab has demonstrated clinical benefit in patients with advanced nonesmallcell lung cancer (NSCLC). A survival advantage was reported compared with docetaxel in a phase II study (POPLAR [a randomized phase II study of atezolizumab (an engineered anti-PDL1 antibody) compared with docetaxel in participants with locally advanced or metastatic NSCLC who have failed platinum therapy]) of patients with previously treated NSCLC with disease progression during platinum-based chemotherapy (hazard ratio [HR] , 0.73; 95% confidence interval [CI] , 0.53-0.99; median overall survival [OS], 12.6 vs. 9.7 months, respectively). 4 A subsequent phase III randomized trial (OAK [a study of atezolizumab compared with docetaxel in participants with locally advanced or metastatic NSCLC who have failed platinumcontaining therapy]; ClinicalTrials.gov identifier, NCT02008227) also demonstrated significant improvement in OS with atezolizumab compared with docetaxel (HR, 0.73; 95% CI, 0.62-0.87; P ¼ .0003) among previously treated patients with locally advanced or metastatic NSCLC, unselected for PD-L1 status. 5 The median OS (intent to treat [ITT]) was 13.8 months with atezolizumab compared with 9.6 months with docetaxel. The improvement in OS was observed regardless of the tumor cell PD-L1 expression level. Additionally, fewer patients who received atezolizumab versus docetaxel experienced treatment-related grade 3/4 adverse events (AEs; 15% vs. 43%, respectively) or discontinued treatment because of AEs (8% vs. 19%, respectively), despite a longer median treatment duration (3.4 vs. 2.1 months, respectively). 5 Based on these data, atezolizumab was granted approval by the US Food and Drug Administration in October 2016 6 and by the European Medicines Agency in September 2017 7 for the treatment of metastatic NSCLC with disease progression (PD) during or after platinum-containing chemotherapy. A major goal in the treatment of metastatic, incurable lung cancer is improving survival and preserving the patient's healthrelated quality of life (HRQoL). As such, patient-reported outcomes (PROs) have become an important measure in the success of a developing immunotherapy. Pain, fatigue, dyspnea, and cough are the most frequent and clinically relevant disease-related symptoms experienced by patients with NSCLC, 8, 9 with significant predictive value for HRQoL. 10, 11 Significant worsening of disease-related symptoms is usually experienced by patients with lung cancer during progression of their disease, 12 in particular, chest and back pain due to local tumor invasion. 13, 14 Most symptoms worsen in frequency and intensity despite efforts at palliation, with chest pain and dyspnea showing the greatest deterioration over time. 15 In lung cancer, worsening of cancer-related symptoms, not only adversely affects patients' HRQoL, but has also been shown to correlate with a lower response to treatment 16 and might be associated with reduced OS. 17 Similarly, research has shown that both physical functioning and patient-reported pain were predictive of survival 18 and could be considered collectively as part of the evaluation of a treatment's benefit/risk profile in NSCLC. Throughout the OAK trial, PRO data were collected to determine the relative effect of atezolizumab and docetaxel on symptom burden, patient functioning, and HRQoL in patients with previously treated, advanced NSCLC. These data are reported in the present report.
Patients and Methods

Study Design
OAK was a randomized, open-label phase III study conducted in 194 oncology centers across 31 countries. The study design and patient eligibility criteria have been previously reported, 5 and the study was performed in full accordance with the guidelines for Good Clinical Practice and the Declaration of Helsinki. Patients had developed PD after 1 to 2 previous cytotoxic chemotherapy regimens, including ! 1 platinum-based therapy regimen. Patients with epidermal growth factor receptor or anaplastic lymphoma kinase genomic alterations were required to have received approved targeted therapy. Patients were randomized 1:1 to receive atezolizumab 1200 mg intravenously every 3 weeks until the loss of clinical benefit as assessed by the investigator in the absence of unacceptable toxicity or symptomatic deterioration attributed to PD or docetaxel 75 mg/m 2 intravenously every 3 weeks until unacceptable toxicity or PD. The primary endpoint for OAK was OS compared between the treatment groups in the ITT primary population (the first 850 of 1225 randomized patients) and the PD-L1 TC1/2/3 or IC1/2/3 populations (patients with PD-L1 expression ! 1% on tumor cells [TCs] or tumor-infiltrating immune cells [ICs] in the primary population). The secondary endpoints were investigator-assessed progression-free survival, objective response rate, duration of response, safety, and PROs. Specifically, prespecified PRO endpoints included (1) assessing the TTD in patient-reported lung cancer symptoms, and (2) assessing the mean change from baseline in lung cancer symptoms, functioning in daily life, and HRQoL.
PRO Assessments
The PROs reflecting lung cancer symptoms, commonly reported treatment-related symptoms (eg, nausea, constipation), functioning in daily life, and HRQoL were collected using 2 self-administered questionnaires that have been routinely used in lung cancer studies: the European Organisation for the Research and Treatment of Cancer (EORTC) quality-of-life questionnaire, QLQ-C30, and its lung cancer module, QLQ-LC13. 19, 20 The EORTC QLQ-C30 comprises 30 items encompassing 5 function scales (ie, physical, role, social, emotional, cognitive), a global health status scale, 3 symptom scales (ie, fatigue, pain, nausea/vomiting), and multiple single-item symptoms scales. The EORTC QLQ-LC13 reports on symptoms specifically related to lung cancer (eg, cough, dyspnea, chest pain) and commonly reported treatment-related symptoms (eg, peripheral neuropathy, sore mouth, alopecia). All function and symptom-related items were measured for the previous week using a 4-point scale, ranging from "not at all" to "very much." In contrast, the global health status scale, which measures HRQoL, comprises 2 questions on a 7-point scale (range, 1-7) and reflects patients' overall health and QoL during the previous week.
The PRO assessments were completed by patients on day 1 of cycle 1 (before any health care interaction), on day 1 of every subsequent cycle, and at the treatment discontinuation visit for both treatment arms, which was within 30 days after the last treatment dose. Assessments were performed before any study assessment and before administration of the study drug.
The EORTC-recommended scoring guidelines were used. A raw score was calculated as the average of items contributing to a scale. A linear transformation was used to standardize the raw scores to a 0-to 100-point range. A ! 10-point score change within a patient or group in any scale (eg, symptoms, function, global health status) was considered to be the threshold of a clinically meaningful change. 21 An increase in the score for the global health status and functioning scales was indicative of improvement, and a decrease in the score for the symptom scales or items was indicative of a reduction in symptom severity.
Statistical Analysis
Patients who completed a PRO assessment at baseline and ! 1 assessments subsequently were defined as the PRO-evaluable population. The PRO-evaluable population was used for all analyses, with the exception of the TTD analysis, which included the ITT population with nonmissing baseline measurements. Apart from the TTD analyses, the PRO data were only interpreted up to cycle 6 for docetaxel, at which point 25% of the PRO-evaluable population remained in the docetaxel arm, limiting the interpretation between the treatment arms.
The TTD was defined as the time from baseline (cycle 1, day 1) until the first ! 10-point change from baseline that was maintained for 2 consecutive cycles or followed by death within 21 days from the last assessment with a ! 10-point decrease. The TTD analyses were prespecified for each lung cancer symptom score (ie, chest pain, dyspnea, cough, and arm/shoulder pain), because these have previously been reported as the most frequent and clinically relevant disease-related chest symptoms by patients with NSCLC. 8, 9 Additional post hoc TTD analyses were conducted for physical function, role function, and HRQoL to understand the cumulative burden of disease and treatment on patients' day-to-day functioning and HRQoL. The TTD analyses were summarized using the KaplanMeier method and a stratified log-rank test (stratified by IC levels, number of previous chemotherapy regimens, and histologic type) was used to compare the TTD between the treatment arms. A Cox proportional hazard model was used to estimate the treatment effect as expressed by the HR and corresponding 2-sided 95% CIs.
Patients with a nonmissing baseline assessment were censored at the last time they had completed their PRO questionnaire, provided their symptoms had not deteriorated up to that point. The mean change from the baseline analyses were used to evaluate the longitudinal course of the patients' experience of disease and treatment and were analyzed descriptively at each on-treatment time point and post hoc by analysis of covariance (ANCOVA) at cycles 5 and 6 for between-group comparisons. A post hoc deterioration rate responder analysis summarized the proportion of patients who had clinically meaningful worsening (! 10-point worsening) from baseline at any point by cycles 5 and 6 for each respective treatment-related symptom item or scale. Post hoc analyses were performed on cycles 5 and 6 because, among the time points with focused interpretation, they were near the median time of progression in the docetaxel arm (median progression-free survival, 4.0 months).
Additional post hoc analyses were conducted to evaluate the value of a prolonged time of receiving treatment with atezolizumab in patients who continued receiving atezolizumab after experiencing PD using the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST, v.1.1). The analyses included calculations of the mean change from baseline to the time of PD using RECIST, v.1.1, in HRQoL, physical function, role function, and lung cancer symptom scores (ie, chest pain, cough, dyspnea) and the mean change from the time of PD (RECIST, v.1.1) until treatment discontinuation because of the loss of clinical benefit in the absence of unacceptable toxicity for symptomatic deterioration attributed to PD.
Results
Patient Characteristics
In the OAK primary analysis population, 850 patients were recruited and randomized to receive either atezolizumab (n ¼ 425) or docetaxel (n ¼ 425). The baseline characteristics of the patients were balanced between the 2 groups.
6 High PRO questionnaire completion rates were observed throughout treatment in both arms of the study. At baseline, 98.1% of the atezolizumab-and 96.5% of the docetaxel-treated patients completed the EORTC QLQ-C30 (Supplemental Figure 1 ; available in the online version). The completion rate was > 80% for all cycles to cycles 27 and 23 in the atezolizumab arm and docetaxel arm, respectively. For the EORTC QLQ-LC13, the completion rates were similar, with 96.7% of the atezolizumab and 95.8% of the docetaxel patients completing the questionnaire at baseline. The completion rates were > 80% for all cycles to cycles 28 and 24 in the atezolizumab arm and docetaxel arm, respectively. The baseline PRO scores from day 1 of cycle 1 are listed in Table 1 . The baseline scores were similar between the 2 arms for all PRO scales. The patients in both arms reported moderate-to-high functioning and HRQoL at baseline. The mean score for global health status on the QLQ-C30 was 61.24 AE 22.31 in the atezolizumab arm and 60.55 AE 22.25 in the docetaxel arm, with a higher score (scale, 0-100) indicating greater HRQoL or functioning. Patients also reported a generally minimal lung cancer symptom burden. The QLQ-LC13 scores across the symptoms (eg, cough, dyspnea, arm/shoulder pain, chest pain, and fatigue) ranged from 3.86 to 38.73, with a lower score (scale, 0-100) indicating milder lung cancer symptoms.
Patient-reported Outcomes
Changes in Patient-reported Function and HRQoL. Patients receiving atezolizumab had a numerically longer TTD in physical function (HR, 0.75; 95% CI, 0.58-0.98) and role function (HR, 0.79; 95% CI, 0.62-1.00) compared with patients receiving docetaxel ( Figure 1A, B) . No differences in the TTD were seen between treatment arms in HRQoL (HR, 0.94; 95% CI, 0.72-1.24; Figure 1C ).
Analyses of the mean change from baseline showed a modest trend toward benefit with atezolizumab relative to docetaxel in HRQoL, physical function, and role function as early as cycle 4 that continued for patients continuing the treatment ( Figure 1D , E).
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The atezolizumab-treated patients reported numerically improved HRQoL from baseline starting at cycle 3 and continuing until cycle 13, when < 25% of PRO-evaluable patients remained in the study and interpretation was limited ( Figure 1F ). Between the treatment arms, the average change from baseline (least squares [LS] mean per ANCOVA) for HRQoL, physical function, and role function showed a trend toward a benefit for atezolizumab at cycles 5 and 6. By cycles 5 and 6, the LS mean difference between the 2 treatment arms was 4.32 (P ¼ .015) and 3.08 (P ¼ .1257) for HRQoL, 3.33 (P ¼ .029) and 6.64 (P < .0001) for physical function, and 2.93 (P ¼ .1959) and 4.72 (P ¼ .0542) for role function, respectively, in favor of atezolizumab.
Changes in Lung Cancer-related Symptoms. Patients in the atezolizumab arm demonstrated a prolonged TTD for patient-reported chest pain compared with the docetaxel arm (HR, 0.71; 95% CI, 0.49-1.05; P ¼ .0823; Figure 2A ), although the data were immature. No differences were seen between the treatment arms for the TTD for other lung cancer symptoms (ie, dyspnea [QLQ-LC13], cough, and arm/shoulder pain; data not shown). Analyses of the mean change from baseline suggested similar modest symptomatic improvement (indicated by a decrease in scores) in both arms across each of the lung cancer symptoms (ie, dyspnea, cough, chest pain [ Figure 2B ], arm/shoulder pain, and fatigue). Minimal LS mean differences in the change from baseline (ANCOVA) scores were seen between the treatment arms for the lung cancer symptoms, although the scores tended to favor atezolizumab at both cycles 5 and 6 ( Table 2 ). The largest LS mean difference (ANCOVA) in the change from baseline scores in the atezolizumab arm was observed for fatigue at 6.27 (P ¼ .0015) and 7.66 (P ¼ .0003) for cycles 5 and 6, respectively.
Changes in Treatment-related Symptoms. Analyses of the mean change from baseline indicated that atezolizumab did not result in Patient Reporting: Atezolizumab Trial in Advanced NSCLC clinically meaningful worsening in commonly reported cancer treatment-related symptoms (ie, nausea/vomiting, diarrhea, constipation, alopecia, peripheral neuropathy, and sore mouth). The average changes from baseline (LS mean per ANCOVA between the 2 treatment arms) showed a trend in favor of atezolizumab at cycles 5 and 6 (Table 2) . By cycles 5 and 6, the largest LS mean difference (ANCOVA) in the change from the baseline scores in the atezolizumab arm were 50.59 (P < .0001) and 47.04 (P < .0001) for alopecia, 12.98 (P < .0001) and 15.71 (P < .0001) for peripheral neuropathy, and 7.29 (P < .0001) and 9.23 (P < .0001) for sore mouth, respectively. Overall, fewer atezolizumab-treated than docetaxeltreated patients experienced clinically meaningful worsening of diar- Figure 2 ; available in the online version).
Evaluation of Prolonged Treatment Time With Atezolizumab After PD. At the point of RECIST, v1.1-determined PD, patients who continued receiving atezolizumab typically experienced less deterioration in HRQoL, physical function, role function, and lung cancer symptoms compared with patients who were given other treatment or who did not receive treatment after PD (Figure 3) . The mean and median change from the baseline scores both indicated that patients who did not receive treatment after PD experienced the greatest worsening among all 3 groups in all scales (with the exception of cough). Only the role function, dyspnea (QLQ-LC13), and fatigue scales demonstrated clinically meaningful worsening at the development of PD relative to baseline by the mean and median scores both for patients who continued with atezolizumab. In contrast, patients who had received other treatment or no treatment after PD experienced clinically meaningful worsening in both mean and median scores on the HRQoL, physical function, role function, fatigue, and dyspnea (QLQ-LC13) scales. The treatment cohort without treatment after PD also demonstrated worsening in dyspnea (QLQ-C30).
Patients who continued treatment with atezolizumab after experiencing RECIST, v1.1-determined PD (n ¼ 162), on average, reported minimal deterioration (< 10 points) in HRQoL for 7 additional cycles, after which, the proportion of patients was 25% of the initial sample (n ¼ 36). Similar patterns emerged for both functioning scales (ie, physical and role function) and each lung cancer symptom (ie, chest pain, cough, dyspnea; Supplemental  Figures 3 and 4 ; available in the online version).
Discussion
Overall, atezolizumab led to a positive benefit over risk for patients compared with chemotherapy, with prolonged TTD in patient-reported functioning (physical function and role function). Atezolizumab also resulted in numerically improved HRQoL from baseline compared with docetaxel and a longer TTD for chest pain, 
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Clinical Lung Cancer September 2018 -445 although no difference was seen between the 2 arms for other lung cancer symptoms. Finally, patients taking atezolizumab experienced no clinically meaningful worsening in treatment-related symptoms. The patients in both treatment arms experienced an initial (up to cycle 2) worsening in HRQoL, physical function, and role function, after which the atezolizumab-treated patients showed a return to baseline or improved scores. A relative benefit in favor of atezolizumab was seen by cycle 4 and continued thereafter in HRQoL, day-to-day function, and lung cancer symptoms, potentially reflecting a delayed treatment effect commonly observed with immunotherapy agents. 22 The lower risk of experiencing key treatment-related symptoms has confirmed the better tolerability of atezolizumab relative to docetaxel. Furthermore, previously reported safety data for atezolizumab have indicated that fewer treatment-related AEs, including grade 3/4 AEs, and fewer discontinuations because of AEs occurred in patients receiving atezolizumab compared with those receiving docetaxel, 5 perhaps suggesting more significant improvement in PROs. The greater tolerability and duration of response seen with atezolizumab relative to docetaxel might be responsible in part for the prolongation in patients' TTD in performing their day-to-day activities (physical function and role function).
5
Figure 
Patient Reporting: Atezolizumab Trial in Advanced NSCLC
Atezolizumab was associated with a nonstatistically significant longer TTD for chest pain compared with docetaxel (HR, 0.71; 95% CI, 0.49-1.05; P ¼ .0823). Modest improvements in lung cancer symptoms were seen in both treatment arms, with numerical differences tending to favor atezolizumab at cycles 5 and 6. Because, in general, patients reported minimal lung cancer symptom burden 
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In a phase III study of nivolumab versus docetaxel in pretreated, advanced squamous NSCLC (CheckMate 017), a similar proportion of patients in each arm (20.0% with nivolumab and 21.9% with docetaxel) showed improvement in lung cancer symptoms at week 12 (assessed using the Lung Cancer Symptom Scale, with assessment every 4 weeks for nivolumab and every 3 weeks for docetaxel). The average symptom burden improved versus baseline with nivolumab during follow-up ( 1 year) but had stabilized with docetaxel within a shorter treatment duration. In addition, an increased time to first disease deterioration (assessed using Lung Cancer Symptom Scale for global HRQoL) was reported with nivolumab compared with chemotherapy. 23, 24 In CheckMate 017, the time to first disease deterioration was also improved with nivolumab compared with docetaxel using the EuroQoL 5-dimension questionnaire, a measure of overall health status. 24, 25 Additional immunotherapy PRO data were reported by the KEYNOTE 010 trial (pembrolizumab versus docetaxel for previously treated, PD-L1 þ , advanced nonesmall-cell lung cancer), a phase III study of pembrolizumab compared with docetaxel for previously treated, PD-L1 þ , advanced NSCLC. 26 PRO data were assessed using the EORTC QLQ-C30 and QLQ-LC13 (administered at cycles 1-3 and every 9 weeks thereafter). Differences in the time to the first composite deterioration of cough, chest pain, and dyspnea, as measured using the EORTC QLQ-LC13, were not found for pembrolizumab, regardless of PD-L1 tumor cell expression in patients with a PD-L1 tumor proportion score of ! 1% or ! 50%. Numerical, but not statistically significant, differences in favor of pembrolizumab compared with docetaxel were found in terms of HRQoL as measured using the global health status score of the EORTC QLQ-LC13. 26 In the OAK study, at the time of PD using the RECIST, v1.1, criteria, patients who continued receiving atezolizumab typically experienced less deterioration of lung cancer symptoms, HRQoL, and day-to-day function (physical and role function) compared with patients who discontinued atezolizumab and received either other treatment or no treatment. These PRO findings correspond with the protocol criteria, which allowed atezolizumab treatment to continue beyond RECIST, v1.1-determined PD if the investigator deemed the patient to be benefitting clinically and if the patient met all the protocol-defined criteria for continuation (D.R. Gandara, et al, unpublished data, 2017). This group of patients demonstrated minimal deterioration in terms of symptom burden, HRQoL, and day-to-day function for ! 7 cycles after PD. These data suggest that atezolizumab treatment beyond PD is associated with a positive benefit/risk profile, at least for patients with good Eastern Cooperative Oncology Group performance status at the time of RECIST, v1.1-determined PD.
The present study used a large sample size of patients and had high questionnaire completion rates across all cohorts. The EORTC QLQ-C30 and its lung cancer module QLQ-LC13 used in the present study are considered the standard instruments for measuring the QoL of patients with lung cancer. 27, 28 As a limitation, the timing of HRQoL assessments was before treatment administration, which might have resulted in a reduced ability to detect treatmentrelated symptoms in the docetaxel arm, some of which are expected to worsen immediately after administration of docetaxel. 29 In future trials, electronic PRO assessments could eliminate this limitation by offering data collection in the patient's home, rather than during their clinic visit. The present study also had limitations in the reporting of PRO data in general. In recent years, more patients have entered trials with fewer symptoms at baseline, as was the case in CheckMate 017, 25 reducing the potential for clinically meaningful improvement in symptoms. A need remains for both novel PRO data collection methods and PRO instruments that offer greater sensitivity to better capture symptom evolution over time within lung cancer populations.
Conclusion
PRO data from the phase III OAK study have indicated that atezolizumab prolongs the time until patients with advanced NSCLC experience limitations in performing their day-to-day activities (physical function and role function) and improves patient HRQoL compared with docetaxel. Our results showed generally modest treatment arm differences, but these were consistent with PRO data reported for other cancer immunotherapies. Overall, these findings support and help our understanding of the clinical benefit and improved tolerability of atezolizumab relative to docetaxel observed in the OAK study. These findings suggest that atezolizumab is a favorable treatment option for patients with previously treated, advanced, or metastatic NSCLC.
PRO assessments should be considered standard tools in the future of cancer immunotherapy research because their use will lead to a better understanding of the effect of immunotherapy on patients' outcomes, beyond the traditional parameters of OS and radiographic endpoints.
Clinical Practice Points
The phase III OAK trial was the first randomized clinical trial to report the results for an antiePD-L1 antibody in the treatment of advanced or metastatic, previously treated NSCLC. Atezolizumab received approval in this treatment setting because it resulted in significant improvement in OS compared with docetaxel, and fewer patients receiving atezolizumab than docetaxel reported treatment-related AEs. Throughout the trial, PROs were collected to report on diseaserelated symptoms and HRQoL. Our study showed that atezolizumab delayed TTD in physical and role function, with a modest improvement from baseline observed. Atezolizumab also resulted in numerically improved HRQoL from baseline. In terms of lung cancer symptoms, atezolizumab prolonged the TTD for chest pain, although both arms saw some reduction. Overall, patients experienced no clinically meaningful worsening in treatment-related symptoms, although the scores favored atezolizumab. The PRO data from the present study support the clinical benefit and tolerability of atezolizumab previously demonstrated in the OAK trial and suggest that patients receiving atezolizumab have a better treatment experience than those receiving docetaxel. Atezolizumab prolonged the time until patients experienced limitations in their day-to-day activities, suggesting that atezolizumab might be a favorable treatment option for those with previously treated, advanced or metastatic NSCLC.
